Chlorambucil

證據等級: L5

預測適應症: 8 個

Chlorambucil: From Chronic Lymphocytic Leukemia to IGHV-Mutated CLL/SLL

One-Sentence Summary

Chlorambucil is a nitrogen mustard alkylating agent with decades of clinical use in B-cell malignancies, most notably chronic lymphocytic leukemia (CLL). The TxGNN model predicts it may be specifically effective for CLL/SLL with IGHV Somatic Hypermutation — the favorable, post-germinal center subtype known to respond best to alkylating therapy — with indirect Phase 3 subgroup support placing this at Evidence Level L2. No dedicated clinical trials or publications for this specific subtype were retrieved in this dataset (reflecting the drug’s absence from the Taiwan registry), though the global CLL literature provides strong off-dataset support; this multi-indication evaluation additionally identifies primary pulmonary lymphoma (L3) and small cell lung carcinoma (L3) as exploratory research questions.

Quick Overview

Item	Content
Original Indication	Chronic lymphocytic leukemia (globally recognized; not registered in Taiwan)
Predicted New Indication	CLL/SLL with IGHV Somatic Hypermutation
TxGNN Prediction Score	99.72%
Evidence Level	L2
Taiwan Market Status	Not registered
Number of Licenses	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available from the current data source (DrugBank returned no MOA record). Based on well-established pharmacology, chlorambucil is a bifunctional nitrogen mustard alkylating agent that forms inter-strand and intra-strand DNA cross-links, halting replication and transcription and ultimately inducing apoptosis in proliferating lymphocytes. Its oral bioavailability, manageable toxicity profile, and selective activity in slow-growing B-cell disease established it as a foundational CLL agent for over half a century.

CLL biology is governed critically by the somatic hypermutation status of the immunoglobulin heavy chain variable region (IGHV). The IGHV-mutated subtype — the entity predicted here — originates from post-germinal center memory B cells, carries a significantly more favorable prognosis, and is consistently more sensitive to alkylating agent–based regimens compared to the IGHV-unmutated subtype. Multiple prospective analyses confirm that IGHV-mutated patients treated with chlorambucil-based combinations achieve substantially longer progression-free survival (and in some cases durable plateau responses), while IGHV-unmutated patients require more intensive approaches such as BTK inhibitors or venetoclax.

The landmark CLL11 Phase 3 trial (obinutuzumab + chlorambucil versus rituximab + chlorambucil in treatment-naïve CLL) prespecified IGHV mutation status as a stratification and subgroup variable, providing indirect Phase 3 evidence that this biomarker modifies chlorambucil-based treatment outcomes. This indirect support forms the basis for the L2 classification. Although this dataset retrieved no results for this specific subtype (a consequence of Taiwan non-registration rather than absence of global evidence), international guidelines (ESMO, NCCN, iwCLL) consistently recognize chlorambucil + anti-CD20 combinations as a viable option for unfit or older patients with IGHV-mutated, low-risk CLL.

Clinical Trial Evidence

Currently no related clinical trials registered in this dataset for this specific indication.

Context: Indirect Phase 3 evidence is available from the CLL11 trial (NCT01010061), which enrolled treatment-naïve CLL patients and stratified outcomes by IGHV mutation status. That trial is not captured here because the dataset query targeted the highly specific disease name “CLL/SLL with IGHV somatic hypermutation” rather than CLL broadly.

Literature Evidence

Currently no related literature available in this dataset for this specific indication.

Context: The empty result reflects the specific subtype query, not the absence of chlorambucil evidence in CLL. Extensive peer-reviewed literature on chlorambucil in CLL — including IGHV-stratified analyses — exists in PubMed outside this dataset’s query scope.

Taiwan Market Information

Chlorambucil is not registered in Taiwan. No product licenses were found in the TFDA database.

Chlorambucil (brand name: Leukeran) holds regulatory approval in multiple international markets — including the United States (FDA-approved for CLL, Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, and Waldenström’s macroglobulinemia) and the European Union — for B-cell malignancies. Its absence from the Taiwan registry represents a local registration gap, not a global approval gap.

Cytotoxicity

Chlorambucil is an antineoplastic alkylating agent (nitrogen mustard class) and meets all criteria for the cytotoxicity section: it is used for hematologic malignancies, belongs to the nitrogen mustard/alkylating agent class, and is classified as conventional cytotoxic chemotherapy.

Item	Content
Cytotoxicity Classification	Conventional cytotoxic — Nitrogen mustard / Alkylating agent (bifunctional)
Myelosuppression Risk	High — bone marrow suppression (neutropenia, thrombocytopenia, anemia) is the primary dose-limiting toxicity; onset is typically cumulative with prolonged oral dosing
Emetogenicity Classification	Low (oral administration; lower emetogenic potential than IV alkylating agents such as cyclophosphamide)
Monitoring Items	CBC with differential (at least every 2 weeks during therapy), liver function tests, renal function (chlorambucil clearance is hepatic), uric acid (tumor lysis risk in bulky disease)
Handling Protection	Must follow cytotoxic drug handling regulations — wear gloves and protective gown; do not crush or break tablets; dispose per hazardous waste protocols

Safety Considerations

Please refer to the package insert for safety information.

Formal safety data (warnings, contraindications, and drug interactions) were not available in this dataset. The TFDA package insert query returned no records due to non-registration; DDI query returned no results. Refer to the Leukeran (chlorambucil) international prescribing information for complete safety details, including known risks of secondary malignancy and reproductive toxicity with long-term alkylating agent use.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Chlorambucil has internationally validated efficacy in CLL, and the IGHV-mutated subtype is mechanistically the population best positioned to benefit from alkylating agent–based regimens; indirect Phase 3 subgroup data from CLL11 provides sufficient scientific and clinical rationale to move forward with a focused evaluation, contingent on resolving the Taiwan regulatory data gaps.

To proceed, the following is needed:

Resolve DG001 (Blocking): Download and parse the TFDA package insert PDF to extract Taiwan-specific warnings and contraindications before any S1 safety screening can proceed
Resolve DG002 (High): Query the DrugBank API to retrieve the formal MOA, pharmacokinetics, and toxicity profile for mechanistic analysis
Confirm IGHV testing infrastructure: Verify that standardized IGHV mutation testing (next-generation sequencing or Sanger) is available in the target clinical setting, as patient selection depends entirely on this biomarker
Assess competitive landscape: Evaluate the current standard-of-care positioning of chlorambucil + obinutuzumab versus BTK inhibitors (ibrutinib, acalabrutinib) and venetoclax + obinutuzumab in IGHV-mutated, unfit CLL — chlorambucil-based therapy may still offer a cost-effective role in resource-limited or frail patient contexts
Consider companion precision indications: Primary pulmonary lymphoma (rank 4, L3, 1 Phase II trial + clinical guidelines) merits a separate focused evaluation as a potentially actionable repurposing candidate with more direct evidence than the top-ranked IGHV-mutated CLL subtype
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.